South London and Maudsley NHS Foundation Trust: Q4 2015-2016 Performance in Delivering Research

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Reason For Closure Of Trial	Comments
2939	10/H7015/26	51787	Observational Study Description F1D-MC-B034(a) Post-Injection Syndrome in Patients with Schizophrenia Receiving Olanzapine Long-Acting Injection	Range Agreed	11	11	Not Available / Not Agreed		0	31/07/2015	Withdrawn By Host	0 Patient
2940	10/H1102/85	66298	Protocol H8A-MC-LZAO Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid 3 Antibody in Patients with Alzheimer's Disease	Range Agreed	1	5	Not Available / Not Agreed		5	26/10/2015	Recruitment Finished	5 patients
2941	13/LO/1183	135274	Randomized, Double-blind, Placebo-controlled, Cross-over Study to Evaluate Functional Magnetic Resonance Imaging (fMRI) of the Brain with Administration of Risperidone, Olanzapine, Haloperidol, Alprazolam or Placebo in Healthy Subjects	Number Agreed	42	42	Date Agreed	31/03/2015	63	03/11/2014	Recruitment Finished	63 Patien
2942	13/LO/0702	116726	A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable At	Range Agreed	1	6	Date Agreed	31/10/2014	5	21/05/2015	Recruitment Finished	7 Patient
2943	12/SC/0443	111575	A Randomized, Double-Blind, Placebo Controlled, 3-period, Proof of Mechanism, Cross-Over Study of Roflumilast (100 or 250 ?g) administered up to Steady State to Evaluate the Effects of Add-on Roflumilast to Second Generation Antipsychotics on Cognitive Imp	Range Agreed	1	15	Date Agreed	31/12/2014	4	25/09/2015	Recruitment Finished	5 patients
2944	14/LO/0359	131838	A Multicenter 26-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to 1 and 2 mg Doses of EVP-6124, an Alpha-7 Nicotinic Acetylcholine Receptor Agonist, as an Adjunctive Pro-cognitive Treatment in Subjects with Schizoph	Range Agreed	1	6	Date Agreed	31/12/2015	4	14/09/2015	Withdrawn By Sponsor	4 Patient